Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia
Authors:
Open Access
- 28 February 2026
- journal article
- review article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 47, 101161
Abstract
No abstract availableKeywords
Funding Information
- Janssen Scientific Affairs
- Legend Biotech
This publication has 33 references indexed in Scilit:
- OA-65 Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study UpdateClinical Lymphoma Myeloma and Leukemia, 2024
- CAR T therapies in multiple myeloma: unleashing the futureCancer Gene Therapy, 2024
- T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyNature Medicine, 2024
- Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort studyThe Lancet Haematology, 2023
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cellsNature, 2022
- Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patientsBlood Cancer Journal, 2021
- Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based StudyClinical Lymphoma Myeloma and Leukemia, 2017
- Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s LymphomaNew England Journal of Medicine, 2015
- Immunity, Inflammation, and CancerCell, 2010
- Nonlymphomatous Malignant Tumors Complicating Hodgkin's DiseaseNew England Journal of Medicine, 1972